EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieÄquivalenzstudieOpen Access · CC BY 4.0

Immunogenicity and safety of Institut Pasteur du Cambodge (IPC) and updated Thai Red Cross (UTRC) intradermal rabies vaccine regimens among healthy adults in India: A phase 4, open label, equivalence randomised controlled trial

Jeromie Wesley Vivian Thangaraj, Padinjaremattathil Thankappan Ullas iD, Balaji Dagadu More iD, Lokesh Shanmugam iD, Saravanakumar Velusamy, Dinesh Gopal, Subashri Ramamoorthy iD, Kanagasabai Kaliaperumal, Mugunthan Narayanan Muthulakshmi, Sandhya Arunachalam, Ramaprabha Ramachandran, Gopinath Ramakrishnan und 16 weitere

PLOS Medicine · 29.10.2026 · 23 (10) · e1005079

DOI: 10.1371/journal.pmed.1005079 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS Medicine, online erschienen am 29.10.2026. Verfasst von Jeromie Wesley Vivian Thangaraj und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease Epidemiology, ICMR National Institute of Epidemiology, Chennai, India. Hauptthemen laut MEDLINE: Rabies Vaccines, Rabies, Post-Exposure Prophylaxis, Immunogenicity, Vaccine. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Shorter rabies post-exposure prophylaxis (PEP) regimens could improve compliance and access by reducing the number of clinic visits and vaccine requirement per patient. We compared the immunogenicity and safety of a 1-week intradermal Institut Pasteur du Cambodge (IPC) regimen with a 1-month intradermal Updated Thai Red Cross regimen (UTRC) using two rabies vaccines widely used in India: Purified Chick Embryo Cell vaccine (PCECV) and the Purified Vero Cell Rabies vaccine (PVRV). Methods and findings We conducted a phase 4, single-centre, open-label randomised controlled equivalence trial among adult healthy volunteers. Participants were block randomised (1:1:1:1) to receive either the IPC (Days 0, 3, 7) or UTRC (Days 0, 3, 7, 28) intradermal regimen with either PCECV or PVRV. Rabies virus neutralising antibody (RVNA) titres were measured up to 1 year. The primary objective of the trial was to determine the immunogenicity of the Intradermal abridged Cambodia regimen with updated intradermal Thai red cross regimen using two different vaccine types among healthy volunteers in India. The primary outcome was geometric mean concentration ratios (GMR) of RVNA on day 42, assessed separately for each vaccine type. Equivalence for each vaccine was predefined as the entire 95% confidence interval for GMR lying between 0.72 and 1.04. The secondary outcomes included proportion of participants with RVNA titres >= 0.5 IU/mL on Days 14, 28, 42, 90, 180, and 365 and vaccine safety. Between October 10, 2023, and December 23, 2023, 400 participants were randomly assigned (100 per group) to PCECV-IPC, PCECV-UTRC, PVRV-IPC, and PVRV-UTRC. 362 (90.5%) completed PEP regimen and blood draw on day 42. In the prespecified modified intention-to-treat analysis, the Day 42 GMR (IPC vs UTRC) was 0.59 (95% CI: 0.47–0.75) for PCECV and 0.76 (95% CI: 0.61–0.95) for PVRV, which did not meet the prespecified equivalence criterion. All participants, irrespective of baseline serostatus, in four groups had RVNA titres ≥0.5 IU/mL at every assessment from day 14–1 year. Adverse events were similar between regimens and mostly mild. There are important limitations in this study. Nearly one-quarter of participants had baseline RVNA titres ≥0.5 IU/mL despite exclusion of participants with a reported history of rabies vaccination or dog bite, suggesting unrecognised prior immunological priming that may have influenced GMC estimates. As the trial was conducted among healthy volunteers rather than people receiving PEP after animal bites, the findings may not fully reflect vaccine performance in routine post-exposure settings.

Conclusion

The IPC regimen did not meet the prespecified equivalence criterion compared to UTRC. All participants achieved RVNA titres ≥0.5 IU/mL indicative of seroprotection from day 14 till 1 year. Policy decisions regarding replacement of UTRC should consider these immunogenicity findings together with compliance, cost, and vaccine availability. Trial Registration The trial was registered with the Clinical Trial Registry – India (CTRI/2023/10/058418). URL: https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=OTAxMDA=&Enc=&userName=) .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rabies VaccinesRabiesPost-Exposure ProphylaxisImmunogenicity, VaccineHumansAdultMaleFemaleInjections, IntradermalYoung AdultIndiaAntibodies, ViralAnimalsAntibodies, NeutralizingAdolescentMiddle AgedHealthy VolunteersRabies virus

Substanzen

Rabies VaccinesAntibodies, ViralAntibodies, Neutralizing

Autor:innen und Institutionen

  • Department of Infectious Disease Epidemiology, ICMR National Institute of Epidemiology, Chennai, India.
  • Rabies Laboratory, Encephalitis Group, ICMR National Institute of Virology, Pune, India.
  • Clinical Trial and Training Centre, Mahatma Gandhi Medical College and Research Institute (MGMCRI), Pondicherry, India.
  • Communicable Diseases Division, Indian Council of Medical Research, New Delhi, India.
  • Department of Epidemiology, ICMR Vector Control Research Centre, Pondicherry, India.
  • Division of Zoonotic Diseases Programme, National Centre for Disease Control, Directorate General of Health Services, Ministry of Health and Family Welfare, New Delhi, India.

ORCID-Profile: Padinjaremattathil Thankappan Ullas, Balaji Dagadu More, Lokesh Shanmugam, Subashri Ramamoorthy, Vijay Vidhyakar Jothi Mani, Siddharth Pugalendhi, Sabarinathan Ramasamy, Anoop Velayudhan, Ala Saritha, Manju Rahi, Simmi Tiwari, Vijay Parashramji Bondre, Manoj V Murhekar

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Thangaraj, J. W. V., Ullas, P. T., More, B. D., Shanmugam, L., Velusamy, S., Gopal, D., Ramamoorthy, S., Kaliaperumal, K., Narayanan Muthulakshmi, M., Arunachalam, S., Ramachandran, R., Ramakrishnan, G., Arunachalam, S., Jothi Mani, V. V., Anthuvan Valli, G., Pugalendhi, S., Ramasamy, S., Thiyagarajan, K., Hanifah, M., …, & Rabies Vaccine Immunogenicity Trial (RVIT) study group (2026). Immunogenicity and safety of Institut Pasteur du Cambodge (IPC) and updated Thai Red Cross (UTRC) intradermal rabies vaccine regimens among healthy adults in India: A phase 4, open label, equivalence randomised controlled trial. PLOS Medicine, 23(10), e1005079. https://doi.org/10.1371/journal.pmed.1005079

Vancouver

Thangaraj JWV, Ullas PT, More BD, Shanmugam L, Velusamy S, Gopal D, et al. Immunogenicity and safety of Institut Pasteur du Cambodge (IPC) and updated Thai Red Cross (UTRC) intradermal rabies vaccine regimens among healthy adults in India: A phase 4, open label, equivalence randomised controlled trial. PLOS Medicine. 2026;23(10):e1005079. doi:10.1371/journal.pmed.1005079

BibTeX
@article{Thangaraj2026,
  author = {Thangaraj, Jeromie Wesley Vivian and Ullas, Padinjaremattathil Thankappan and More, Balaji Dagadu and Shanmugam, Lokesh and Velusamy, Saravanakumar and Gopal, Dinesh and Ramamoorthy, Subashri and Kaliaperumal, Kanagasabai and Narayanan Muthulakshmi, Mugunthan and Arunachalam, Sandhya and Ramachandran, Ramaprabha and Ramakrishnan, Gopinath and Arunachalam, Suresh and Jothi Mani, Vijay Vidhyakar and Anthuvan Valli, Ganeshnee and Pugalendhi, Siddharth and Ramasamy, Sabarinathan and Thiyagarajan, Karunakaran and Hanifah, Mohamed and Joy, Sam and Velayudhan, Anoop and Egambaram, Suganya and Saritha, Ala and Rahi, Manju and Tiwari, Simmi and Bondre, Vijay Parashramji and Murhekar, Manoj V and Rabies Vaccine Immunogenicity Trial (RVIT) study group, Rabies Vaccine Immunogenicity Trial (RVIT) study group},
  title = {Immunogenicity and safety of Institut Pasteur du Cambodge (IPC) and updated Thai Red Cross (UTRC) intradermal rabies vaccine regimens among healthy adults in India: A phase 4, open label, equivalence randomised controlled trial},
  journal = {PLOS Medicine},
  year = {2026},
  volume = {23},
  number = {10},
  pages = {e1005079},
  doi = {10.1371/journal.pmed.1005079}
}
Kostenlos starten →